Stockscreener 앱 받기
1.88
1.57%
-0.03
전일 마감가:
$1.91
열려 있는:
$1.89
하루 거래량:
863.74K
Relative Volume:
0.52
시가총액:
$184.32M
수익:
-
순이익/손실:
$-134.24M
주가수익비율:
-1.0621
EPS:
-1.77
순현금흐름:
$-121.34M
1주 성능:
+28.77%
1개월 성능:
-23.89%
6개월 성능:
-74.59%
1년 성능:
-59.04%
1일 변동 폭
$1.80
$1.90
1주일 범위
$1.40
$1.96
52주 변동 폭
$1.285
$7.85
아넥손 Stock (ANNX) Company Profile
명칭
Annexon Inc
전화
(650)-822-5500
주소
1400 SIERRA POINT PARKWAY, BRISBANE
ANNX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANNX
Annexon Inc
|
1.88 | 184.32M | 0 | -134.24M | -121.34M | -1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
아넥손 Stock (ANNX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-03-01 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-12-21 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2023-10-30 | 개시 | Wells Fargo | Overweight |
| 2023-05-26 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2023-05-25 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2022-09-16 | 개시 | Jefferies | Buy |
| 2022-09-09 | 개시 | BTIG Research | Buy |
| 2021-11-30 | 개시 | H.C. Wainwright | Buy |
| 2021-09-23 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-01-26 | 개시 | Needham | Buy |
| 2020-08-18 | 개시 | BofA Securities | Buy |
| 2020-08-18 | 개시 | Cowen | Outperform |
| 2020-08-18 | 개시 | JP Morgan | Overweight |
모두보기
아넥손 주식(ANNX)의 최신 뉴스
Investors in cash trouble should check out Annexon Inc (ANNX) - Sete News
SEC Form DEFA14A filed by Annexon Inc. - Quantisnow
JP Morgan analysts upgrades an Overweight rating for Annexon Inc (ANNX) - knoxdaily.com
Annexon, Inc. (NASDAQ:ANNX) Shares Purchased by Geode Capital Management LLC - Defense World
ANNX’s price-to-sales ratio: Is it a good investment opportunity? - uspostnews.com
Annexon Inc (ANNX) Stock: A Year of Market Fluctuations - investchronicle.com
Alliancebernstein L.P. Reduces Stock Holdings in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon, Inc. (NASDAQ:ANNX) Sees Large Decrease in Short Interest - Defense World
JPMorgan Chase & Co. Has $7.75 Million Position in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) | ANNX Stock News - GuruFocus
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Annexon Strengthens Team with Strategic Equity Package: Inside the $1.54 Share Grant - Stock Titan
Annexon: With IGOS Study Completion, Pre-BLA Meeting In 1st Half 2025 On Deck (NASDAQ:ANNX) - Seeking Alpha
Vanguard Group Inc. Buys 576,625 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
KLP Kapitalforvaltning AS Takes $98,000 Position in Annexon, Inc. (NASDAQ:ANNX) - Defense World
American Century Companies Inc. Has $916,000 Position in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon's Investigational Drug Shows Rapid Recovery And Durable Benefit In Rare Neurological Disorder - AOL.com
Why Annexon Inc. (ANNX) Went Down On Thursday? - Yahoo Finance
Annexon Touts ‘Rapid’ and ‘Durable’ Improvements for Targeted Guillain-Barré Therapy - BioSpace
Annexon Highlights Pivotal Data on First Potential Targeted Ther - GuruFocus
Annexon Cites 'Durable Benefit' of Tanruprubart in Guillain-Barre Syndrome Trial - MarketScreener
Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting - The Manila Times
Annexon Highlights Pivotal Data on First Potential Targeted - GlobeNewswire
First-Ever Targeted GBS Therapy Achieves Remarkable Recovery Rates in Landmark Trial - Stock Titan
Prudential Financial Inc. Boosts Holdings in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon stock hits 52-week low at $1.73 amid sharp annual decline - Investing.com
Annexon Highlights Leadership in Advancing Clinical - GlobeNewswire
First-Ever Targeted GBS Treatment: Annexon's Phase 3 Data Could Change Patient Care - Stock Titan
Teacher Retirement System of Texas Makes New $106,000 Investment in Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon Inc (ANNX) may enjoy gains as insiders got busy in the recent days - knoxdaily.com
Here's Why We're Not Too Worried About Annexon's (NASDAQ:ANNX) Cash Burn Situation - Yahoo Finance
135,000 Shares in Annexon, Inc. (NASDAQ:ANNX) Purchased by Swiss National Bank - Defense World
Annexon Inc (NASDAQ: ANNX) Slashes -7.49%: The Most Likely Path Going Forward - Stocks Register
Annexon, Inc. (NASDAQ:ANNX) Shares Acquired by Charles Schwab Investment Management Inc. - Defense World
Annexon stock hits 52-week low at $2.28 amid market challenges By Investing.com - Investing.com South Africa
Annexon stock hits 52-week low at $2.28 amid market challenges - Investing.com Australia
Bank of New York Mellon Corp Acquires 6,226 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Annexon Inc (NASDAQ: ANNX): Down -60.53% In 2025, Outlook Remains Negative - Stocks Register
Annexon Inc (ANNX) With A Potential Upside Of More Than -460.0% - Stocks Register
Quarterly Metrics: Quick and Current Ratios for Annexon Inc (ANNX) - The Dwinnex
Annexon (ANNX) Projected to Post Earnings on Tuesday - Defense World
Annexon Strengthens Team with 35,000-Share Stock Option Grant to Key New Hire - StockTitan
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
19,895 Shares in Annexon, Inc. (NASDAQ:ANNX) Acquired by Arizona State Retirement System - Defense World
Wells Fargo Predicts Up to ~440% Rally for These 2 ‘Strong Buy’ Stocks - markets.businessinsider.com
Annexon: Despite Major Catalysts, Stock Is Trading Almost At Cash (NASDAQ:ANNX) - Seeking Alpha
Annexon, Inc. (NASDAQ:ANNX) Given Average Rating of “Buy” by Analysts - Defense World
We're Hopeful That Annexon (NASDAQ:ANNX) Will Use Its Cash Wisely - simplywall.st
Rhumbline Advisers Purchases 5,854 Shares of Annexon, Inc. (NASDAQ:ANNX) - Defense World
Q1 Earnings Forecast for Annexon Issued By HC Wainwright - Defense World
Annexon Biosciences: Promising Developments and Strategic Milestones Justify Buy Rating - TipRanks
아넥손 (ANNX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
36.06%
자본화:
|
볼륨(24시간):